Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • ELISA
  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

Influenza A, H1N1 New Caledonia 20/99, Hemagglutinin, Recombinant (Full Length)

  • Product Code: X2565
  • Size: 10 µg
  • Availability: In Stock In Stock
  • Price (USD): $388

Cat #

X2565		 Quantity:      

Data Sheet

Product Name

Influenza A, H1N1 New Caledonia 20/99, Hemagglutinin, Recombinant (Full Length)

Host/Source

Sf9 cells

Product Type

Recombinant Protein

Applications

Elisa, WB

Purification

≥ 90% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: ≤ 0.1ng/ug (IEU/ug).

Size

10 µg

Price (USD)

$388

Background

Influenza virus is a single-stranded RNA virus, segmented, 70nm in diameter and enveloped. Strains are described by geographic origin, strain number, year of isolation and hemagglutination (H) and neuraminidase (N) antigens.

Immunogen

Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 72kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.

Positive Control

Recombinant full-length H1N1 A/New Caledonia/20/99 (MW 7.5kD) is glycosylated with N-linked sugars and produced using baculovirus vectors in insect cells. The insect cells were infected with A9440.1a, recombinant baculovirus expressing recombinant H1N1 A/New Caledonia/20/99. H1N1 New Caledonia shows 90% similarity to the A/PR/8/34 amino acid sequence.

Formulation

Supplied as a sterile solution in 10mM sodium phosphate, pH 7.2, 150mM sodium chloride.

Customer Storage

May be stored at 4°C for short-term only. For long-term storage, add 0.1% HSA or BSA, store at -20°C. Aliquots are stable for at least 6 months at -20°C.

Target Molecular Weight

72 kDa

References

1. Wrammert, J., et al. “Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.” J. of Exp. Med. (2011), 208, 181-193.